Media Coverage

ELIAS canine cancer vaccine yields positive study results


Aug 07, 2018 - Animal Pharm
By Sian Lazell

ELIAS Animal Health has gained positive preliminary results in a study of its cancer immunotherapy against canine osteosarcoma.

The study showed ELIAS' autologous cancer vaccine facilitated "impressive survival times and minimal side effects".

The vaccine is based on ELIAS' T cell technology. The immunotherapeutic is being distributed as an experimental product under '9 CFR 103.3' to veterinarians treating dogs diagnosed with cancer. Efficacy and safety of the vaccine have not yet been established.

Final results of the study are expected in Q3 this year, along with supporting data from a separate study conducted in collaboration with the Animal Clinical Investigation network of veterinary hospitals.

One in four dogs will be affected by cancer in their lifetimes and it is the leading cause of death in dogs over the age of two.

Noe Reyes, medical director at ELIAS, said: "There has been growing frustration in the veterinary profession with current treatment options, including chemotherapy and radiation, which have only modestly improved outcomes over the past 20 years.

"We are very encouraged by the positive treatment outcomes reported and look forward to starting our pivotal osteosarcoma trial evaluating this T cell-based immunotherapy in a broader population. Compared to historical treatment outcomes (amputation and amputation plus chemotherapy), our preliminary results indicate longer median survival times and minimal adverse effects. Seeing metastatic lesions resolve or stay relatively static in some of our patients also highlights the promise of this therapeutic approach for treating cancer in dogs."

In June, ELIAS significantly expanded its leadership team. The Kansas-based firm named Steve Sewell chief operating officer, added Lee Herron to its scientific advisory board, and added Julia Stephanus and Kip Wiggins to its board.

At the time of the appointments, the firm also revealed it would be pursuing a financing round estimated at $4 million in 2018.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum